BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Reolysin: Preliminary Phase II data

Preliminary data from the first stage of the open-label, U.S. Phase II REO 017 trial showed that first-line therapy with IV Reolysin plus Gemzar gemcitabine every 3 weeks met the primary endpoint of >=3 patients experiencing clinical benefit defined by complete or...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >